EBITDA Margin: 22.23%
Is the EBITDA margin high or low?
The EBITDA margin of 22.23% is 27% below its 5-year average of 30.43%, around the middle of its 5-year range (9.78%–39.49%).
As of Saturday, June 27, 2026. 0.79% above its 12-month average of 22.06%.
NRC EBITDA Margin
Reported quarterly EBITDA margin; no daily interpolation.
NRC Average EBITDA Margin Chart
NRC Current vs Average EBITDA Margin Chart
NRC EBITDA Margin Metrics
EBITDA MARGIN
22.23%
EBITDA MARGIN AVG TTM
22.06%
EBITDA MARGIN AVG 3Y
29.08%
EBITDA MARGIN AVG 5Y
32.10%
EBITDA MARGIN AVG 10Y
33.57%
EBITDA MARGIN AVG 15Y
32.96%
EBITDA MARGIN AVG 20Y
31.74%
CURRENT VS TTM AVG
+0.79%
CURRENT VS 3Y AVG
-23.55%
CURRENT VS 5Y AVG
-30.74%
CURRENT VS 10Y AVG
-33.78%
CURRENT VS 15Y AVG
-32.54%
CURRENT VS 20Y AVG
-29.95%
NRC Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| National Research Corporation (NRC) | $468.99M | 22.23% | 22.06% | 29.08% | 32.10% |
| Shoulder Innovations, Inc. (SI)vs › | $472.62M | -48.80% | -44.09% | -45.35% | -45.35% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -114.42% | -123.66% | -106.79% | -92.91% |
| Teladoc Health, Inc. (TDOC)vs › | $1.51B | 3.96% | -13.21% | -146.19% | -104.68% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.21B | 16.41% | 1.22% | -1.65% | 4.31% |
| TransMedics Group, Inc. (TMDX)vs › | $2.37B | 22.42% | 17.70% | -0.76% | -37.34% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.56B | 6.82% | 6.08% | -0.44% | -8.67% |
| Oscar Health, Inc. (OSCR)vs › | $7.72B | -3.14% | -1.08% | -5.02% | -19.32% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.00B | 18.42% | 17.41% | 19.12% | 20.05% |
| Universal Health Services, Inc. (UHS)vs › | $9.12B | 15.05% | 14.69% | 13.35% | 14.10% |
Margin Comparison
Gross Margin
55.9%
EBITDA Margin
22.2%
Operating Margin
14.1%
Net Margin
6.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EBITDA Margin FAQ
- What is the EBITDA margin for National Research Corporation (NRC)?
- The EBITDA margin for NRC stock is 22.23%.
- Is National Research Corporation's EBITDA margin high or low?
- The EBITDA margin of 22.23% is 27% below its 5-year average of 30.43%, around the middle of its 5-year range (9.78%–39.49%).
- What is the TTM average EBITDA margin for National Research Corporation (NRC)?
- The TTM average EBITDA margin for NRC stock is 22.06%.
- What is the 3Y average EBITDA margin for National Research Corporation (NRC)?
- The 3Y average EBITDA margin for NRC stock is 29.08%.
- What is the 5Y average EBITDA margin for National Research Corporation (NRC)?
- The 5Y average EBITDA margin for NRC stock is 32.10%.
- What is the 10Y average EBITDA margin for National Research Corporation (NRC)?
- The 10Y average EBITDA margin for NRC stock is 33.57%.
- What is the 15Y average EBITDA margin for National Research Corporation (NRC)?
- The 15Y average EBITDA margin for NRC stock is 32.96%.
- What is the 20Y average EBITDA margin for National Research Corporation (NRC)?
- The 20Y average EBITDA margin for NRC stock is 31.74%.
NRC EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 22.23% |
| 2025-12-31 | 19.36% |
| 2025-09-30 | 28.70% |
| 2025-06-30 | 9.78% |
| 2025-03-31 | 30.22% |
| 2024-12-31 | 30.09% |
| 2024-09-30 | 26.59% |
| 2024-06-30 | 29.63% |
| 2024-03-31 | 28.90% |
| 2023-12-31 | 34.58% |
| 2023-09-30 | 30.33% |
| 2023-06-30 | 30.10% |
| 2023-03-31 | 28.54% |
| 2022-12-31 | 35.70% |
| 2022-09-30 | 32.91% |
| 2022-06-30 | 34.29% |
| 2022-03-31 | 33.85% |
| 2021-12-31 | 37.16% |
| 2021-09-30 | 38.49% |
| 2021-06-30 | 38.09% |
| 2021-03-31 | 39.49% |
| 2020-12-31 | 37.58% |
| 2020-09-30 | 41.42% |
| 2020-06-30 | 34.27% |
| 2020-03-31 | 37.11% |
| 2019-12-31 | 40.51% |
| 2019-09-30 | 35.88% |
| 2019-06-30 | 36.89% |
| 2019-03-31 | 38.50% |
| 2018-12-31 | 35.45% |
| 2018-09-30 | 35.16% |
| 2018-06-30 | 32.41% |
| 2018-03-31 | 33.02% |
| 2017-12-31 | 33.01% |
| 2017-09-30 | 28.51% |
| 2017-06-30 | 33.73% |
| 2017-03-31 | 36.63% |
| 2016-12-31 | 34.94% |
| 2016-09-30 | 31.17% |
| 2016-06-30 | 31.06% |
| 2016-03-31 | 32.20% |
| 2015-12-31 | 33.02% |
| 2015-09-30 | 30.18% |
| 2015-06-30 | 30.20% |
| 2015-03-31 | 26.05% |
| 2014-12-31 | 29.51% |
| 2014-09-30 | 34.24% |
| 2014-06-30 | 30.18% |
| 2014-03-31 | 35.86% |
| 2013-12-31 | 30.41% |
| 2013-09-30 | 30.95% |
| 2013-06-30 | 28.93% |
| 2013-03-31 | 32.79% |
| 2012-12-31 | 31.22% |
| 2012-09-30 | 31.78% |
| 2012-06-30 | 31.17% |
| 2012-03-31 | 32.69% |
| 2011-12-31 | 32.89% |
| 2011-09-30 | 29.68% |
| 2011-06-30 | 27.66% |
| 2011-03-31 | 35.08% |
| 2010-12-31 | 23.18% |
| 2010-09-30 | 29.48% |
| 2010-06-30 | 26.29% |
| 2010-03-31 | 37.10% |
| 2009-12-31 | 30.73% |
| 2009-09-30 | 31.06% |
| 2009-06-30 | 26.43% |
| 2009-03-31 | 32.76% |
| 2008-12-31 | 29.99% |
| 2008-09-30 | 28.34% |
| 2008-06-30 | 27.17% |
| 2008-03-31 | 29.49% |
| 2007-12-31 | 22.93% |
| 2007-09-30 | 34.27% |
| 2007-06-30 | 27.87% |
| 2007-03-31 | 27.50% |
| 2006-12-31 | 24.85% |
| 2006-09-30 | 34.49% |
| 2006-06-30 | 24.77% |
| 2006-03-31 | 25.01% |
| 2005-12-31 | 32.07% |
| 2005-09-30 | 37.34% |
| 2005-06-30 | 27.80% |
| 2005-03-31 | 25.19% |
| 2004-12-31 | 30.07% |
| 2004-09-30 | 35.64% |
| 2004-06-30 | 28.33% |
| 2004-03-31 | 31.20% |
| 2003-12-31 | 35.41% |
| 2003-09-30 | 32.93% |
| 2003-06-30 | 31.46% |
| 2003-03-31 | 32.32% |
| 2002-12-31 | 39.42% |
| 2002-09-30 | 37.29% |
| 2002-06-30 | 40.25% |
Related Metrics
About National Research Corporation
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Trent Green